Dermaseptin Peptide Derivatives Kill MDR Klebsiella and Staph at Low Concentrations | Research

The takeaway

Four dermaseptin S4 and B2 derivatives showed antibacterial activity against MDR K. pneumoniae and S. epidermidis with MICs of 6.25-25 μg/mL and concentration-dependent cytotoxicity.

6.25-25 μg/mL MIC
Frog-derived peptide derivatives effective against two major MDR hospital pathogens at therapeutically relevant concentrations

What the researchers found

Four dermaseptin derivatives (K4K20S4, K4S4(1-16), B2, K3K4B2) showed MICs 6.25-25 μg/mL and MBCs 12.5-50 μg/mL against MDR K. pneumoniae and S. epidermidis, with concentration-dependent cytotoxicity.

Why it matters

K. pneumoniae and S. epidermidis cause devastating hospital infections with increasingly limited antibiotic options. Frog-derived peptide alternatives could fill this gap.

How the study worked

Synthesis of four dermaseptin S4/B2 derivatives, MIC/MBC determination against MDR K. pneumoniae and S. epidermidis, and cytotoxicity assessment via MTT assay on HEp-2 cells.

What this study cannot tell us

In vitro only. Therapeutic window between antimicrobial and cytotoxic concentrations needs optimization. In vivo efficacy not tested.

How to read the evidence

Standard in vitro AMP characterization. Promising activity levels needing in vivo validation.

When this study was published

Published in 2025.

The bigger picture

Frog skin remains one of nature's richest sources of antimicrobial peptides, with dermaseptins showing consistently promising activity against hospital superbugs.

Questions still open

Can the therapeutic window be improved through further sequence optimization?
Would these derivatives show activity against other ESKAPE pathogens?
What is the mechanism of action enabling dual Gram-positive/negative activity?

Common questions

What are dermaseptins?

Antimicrobial peptides naturally produced in frog skin. They evolved over millions of years to protect frogs from skin infections and show potent activity against bacteria that resist human antibiotics.

Can frog peptides treat human infections?

In the lab, yes — these derivatives kill two of the most dangerous hospital bacteria at low concentrations. Further development is needed to create formulations suitable for treating human infections.

Read the original research

Antibacterial activity of peptide derivatives of dermaseptins against multidrug-resistant Klebsiella pneumoniae and Staphylococcus epidermis.

Biochemistry and biophysics reports, 45, 102449

View on PubMed ↗Publisher’s paper ↗

Citation

Haddad, Houda; Al-Rashidi, Reyadh R; Loghmari, Ahmed; Sahtout, Wissal; Boukadida, Raja; Dahmene, Rihem; Ettouil, Emeny; Othman, Houcemeddine; Ouahchi, Ines; Zaϊri, Amira. (2026). Antibacterial activity of peptide derivatives of dermaseptins against multidrug-resistant Klebsiella pneumoniae and Staphylococcus epidermis.. Biochemistry and biophysics reports, 45, 102449. https://doi.org/10.1016/j.bbrep.2026.102449